Cordlife Group Limited
1 Yishun Industrial Street 1 • A'Posh Bizhub • #06-01/09 • Singapore 768160
Phone (65) 6238 0808 • Fax (65) 6238 1108
Find Out More • info@cordlife.com • For Cordlife Parents • customercare@cordlife.com
Company Registration Number: 200102883E

**PRESS RELEASE**

# Cordlife 1H2026 loss down by 42.2% to $2.7 million

- Cost optimization initiatives reduced 2Q2026 net loss by 68.7% to $0.94 million
- 1H2026 gross profit margin improves to 58.2%
- Hong Kong revenue growth of 5%, reinforcing position as Group's largest market in the absence of new collections in Singapore

**Singapore, 13 August 2026** – Cordlife Group Limited ("**Cordlife**" or the "**Company**", and together with its subsidiaries, the "**Group**") announced today the Group's financial results for the six months ended 30 June 2026 ("**1H2026**"), reporting a significant reduction in losses amid cost-optimization initiatives and growth in its Hong Kong business.

Group net loss declined by 42.2% to $2.7 million for the six months ended 30 June 2026 (1H2026), from a $4.6 million loss in the same period last year (1H2025). Net loss for the second quarter shrank to under $1 million from nearly $3 million in 2Q2025, down 68.7%.

**Financial Highlights (unaudited)**

| S$'000 | 2Q2026 | 2Q2025 | Change (%) | 6M2026 | 6M2025 | Change (%) |
|---|---|---|---|---|---|---|
| Revenue | 8,301 | 9,609 | (13.6) | 17,291 | 19,186 | (9.9) |
| Gross Profit | 4,859 | 5,580 | (12.9) | 10,068 | 10,945 | (8.0) |
| Loss before income tax from operations | (988) | (2,896) | (65.9) | (2,711) | (4,884) | (44.5) |
| Loss before tax | (873) | (2,705) | (67.7) | (2,576) | (4,370) | (41.1) |
| Income tax expense | (64) | (286) | (77.6) | (83) | (233) | (64.4) |
| Net Loss | (937) | (2,991) | (68.7) | (2,659) | (4,603) | (42.2) |
| | | | | | | |
| Gross Profit margin (%) | 58.5 | 58.1 | 0.4pp*. | 58.2 | 57.0 | 1.2pp |
| Net Loss margin (%) | (11.3) | (31.1) | 19.8pp | (15.4) | (24.0) | 8.6pp |

*pp = percentage points

Group revenue for 1H2026 declined 9.9% year-on-year to $17.3 million, primarily due to the continued absence of new business in Singapore, together with softer contributions from the Philippines and Indonesia. This was partially offset by revenue growth in Hong Kong, while Malaysia and India remained relatively stable.

Although Cordlife Singapore successfully renewed its cord blood banking and human tissue banking licenses with the Ministry of Health in January 2026, revenue remained impacted by the ongoing suspension of new cord blood collections that was imposed in November 2025. Cordlife Singapore continues to work closely with the regulators as it works towards a resumption of new cord blood collections.

Hong Kong delivered revenue growth of nearly 5% to $5.2 million in 1H2026, from $4.9 million in 1H2025. As the Group's largest revenue contributor, the Hong Kong business benefitted from strong renewal rates, demand for higher-value service offerings, and its market-leading position, providing resilience to the Group's overall regional performance.

Cordlife Group Limited
1 Yishun Industrial Street 1 • A'Posh Bizhub • #06-01/09 • Singapore 768160
Phone (65) 6238 0808 • Fax (65) 6238 1108
Find Out More • info@cordlife.com • For Cordlife Parents • customercare@cordlife.com
Company Registration Number: 200102883E

Gross profit for the half year was $10.1 million, down 8.0% from S$10.9 million in 1H2025. Gross profit margin improved to 58.2% from 57.0% in 1H2025, supported by cost optimization initiatives, particularly in the second quarter.

As part of its ongoing strategy to streamline operations and sharpen its focus on its core cord blood banking business, the Group is progressively scaling back its diagnostic activities in Indonesia, India and Malaysia. It intends to focus its offering of diagnostic services in selected markets where such services remain commercially practicable and strategically aligned with its long-term growth objectives.

Notwithstanding the progress made, uncertainties remain in relation to the ongoing legal proceedings arising from the FY2023 temperature excursion and the assessment of the remaining low-risk cryogenic storage tanks. The outcomes of these matters remain pending and could affect the Group's operations, financial position and future prospects. The Group continues to monitor these developments closely and will provide further updates as appropriate.

Group CEO and Group Executive Director Ms Chen Xiaoling said: "We are encouraged by the meaningful progress made in the first half of the year, particularly in the improvement in our second-quarter fundamental results. The Group is fully committed towards, positioning for full resumption of business in Singapore and have used this period to strengthen our internal processes and operational discipline. We remain firmly committed to building on this momentum and driving the Group towards full recovery and sustained growth.

We are especially pleased with the improved performance of our Hong Kong subsidiary, which continues to build on its frontrunning position in that market, and we see meaningful growth potential across our other regional businesses as they draw on the strengths of the Group's network."

**- End -**

**About Cordlife Group Limited**

Established in May 2001, Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a leading company dedicated to safeguarding the well-being of mother and child. The Group has been listed on the Mainboard of the Singapore Exchange since 2012 and is a pioneer in private cord blood banking in Asia. Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities and direct operations in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, Hong Kong, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks and it is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife has also established its presence in Vietnam, Macau and Brunei. Beyond cord blood, cord lining and cord tissue banking, Cordlife offers a comprehensive suite of diagnostic services for the family including urine-based newborn metabolic screening, non-invasive prenatal testing and family genetic screening services. Quality and customer focus are amongst some of the cornerstones of Cordlife. For more information, visit http://cordlife.listedcompany.com

---

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Catherine Ong Associates
3 Pickering Street, #02 - 01, Nankin Row
China Square Central
Singapore 048660

CONTACT : Romesh Navaratnarajah

OFFICE : (65) 9016 0920

EMAIL : romesh@catherineong.com